Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Regeneron Pharma (REGN) PT Raised to $480 at Oppenheimer
February 7, 2019 8:15 AM ESTOppenheimer analyst Hartaj Singh raised the price target on Regeneron Pharma (NASDAQ: REGN) to $480.00 (from $440.00) while maintaining a Outperform rating.
Singh commented, "REGN reported 4Q18 sales/earnings and provided a business update on 02/06. The company's Eylea US (and ex-US) sales were 5-9% above OPCO... More
Regeneron Pharma (REGN) PT Raised to $410 at BMO Capital
February 6, 2019 3:25 PM ESTBMO Capital analyst Brian Skorney raised the price target on Regeneron Pharma (NASDAQ: REGN) to $410.00 (from $388.00) while maintaining a Market Perform rating, saying they are incrementally positive on earnings.
Skorney commented, "Regeneron reported strong fourth quarter earnings coming in ahead of both top- and... More
